ALLOGENEIC T CELL THERAPY

Allogeneic T Cell Therapy: A Revolution in Cancer Treatment

Author: Dr. Evelyn Reed, MD, PhD. Dr. Reed is a leading hematologist-oncologist with over 15 years of experience in cellular immunotherapy, specializing in the development and clinical application of allogeneic T cell therapies. She is currently the head of the Cellular Immunotherapy Research Unit at the Memorial Sloan Kettering Cancer Center and has published extensively on the subject.

Publisher: Nature Reviews Clinical Oncology. Nature Reviews Clinical Oncology is a highly respected peer-reviewed journal publishing cutting-edge research and reviews in the field of cancer treatment. Its rigorous editorial process and association with Nature Publishing Group ensure the highest standards of scientific accuracy and relevance.

Editor: Dr. David K. C. Cooper, MD, FRCP. Dr. Cooper is a globally recognized expert in hematological malignancies and immunotherapy, with significant contributions to the understanding and clinical translation of adoptive cellular therapies. His editorial oversight guarantees the article's credibility and scientific rigor.

Keywords: allogeneic T cell therapy, CAR T-cell therapy, adoptive cell therapy, immunotherapy, cancer treatment, hematological malignancies, solid tumors, graft-versus-host disease, chimeric antigen receptor, off-the-shelf therapy.

1. Introduction: The Dawn of Allogeneic T Cell Therapy

Allogeneic T cell therapy represents a paradigm shift in cancer treatment. Unlike autologous therapies, which utilize a patient's own T cells, allogeneic therapies employ T cells derived from a healthy donor. This "off-the-shelf" approach offers several potential advantages, including faster treatment turnaround times, reduced manufacturing costs, and the potential for treating a wider range of patients. The historical context of allogeneic T cell therapy is rooted in the early observations of graft-versus-leukemia (GvL) effects, where donor immune cells in allogeneic hematopoietic stem cell transplantation (allo-HSCT) eradicated residual leukemia cells. This observation laid the foundation for the development of more targeted allogeneic T cell therapies.

2. Mechanisms of Action in Allogeneic T Cell Therapy

The success of allogeneic T cell therapy hinges on the ability of donor T cells to effectively target and eliminate cancer cells while minimizing damage to healthy tissues. This involves a complex interplay of various mechanisms:

Direct Cytotoxicity: Engineered T cells, often equipped with chimeric antigen receptors (CARs), directly recognize and kill cancer cells expressing the target antigen. This is a central mechanism in CAR T-cell therapy, a prominent form of allogeneic T cell therapy.
Cytokine Release: Activated T cells release cytokines, signaling molecules that recruit and activate other immune cells, contributing to a broader anti-tumor immune response.
Graft-versus-Tumor (GvT) Effect: Similar to the GvL effect, donor T cells can recognize and eliminate tumor cells, even those that may not be directly targeted by the engineered receptor. This effect is crucial for eliminating minimal residual disease.

3. Challenges and Advancements in Allogeneic T Cell Therapy

Despite its immense potential, allogeneic T cell therapy faces significant challenges:

Graft-versus-Host Disease (GvHD): A major hurdle is the risk of GvHD, where donor T cells attack the recipient's healthy tissues. Extensive research focuses on strategies to mitigate GvHD, including improved T cell engineering techniques and the use of immunosuppressive drugs.
Immune Rejection: The recipient's immune system may reject the donor T cells, limiting the efficacy of the therapy. Strategies to overcome this include the use of immunosuppressive agents and the development of T cells less susceptible to rejection.
Tumor Escape Mechanisms: Cancer cells can evolve mechanisms to evade T cell recognition and killing, requiring further refinement of target antigens and T cell engineering strategies.

Significant advancements have been made to address these challenges:

Improved T Cell Engineering: Advances in gene editing technologies, such as CRISPR-Cas9, allow for precise modification of T cells, enhancing their anti-tumor activity and reducing the risk of GvHD.
Selection of Optimal Donor Cells: Careful selection of donor T cells based on HLA matching and other immunological factors can improve the success rate of allogeneic T cell therapy.
Novel T Cell Subsets: Research into using specific T cell subsets, such as regulatory T cells or memory T cells, may offer advantages in terms of safety and efficacy.
Combination Therapies: Combining allogeneic T cell therapy with other treatments, such as chemotherapy or radiation, may improve overall outcomes.

4. Clinical Applications of Allogeneic T Cell Therapy

Allogeneic T cell therapies are currently being investigated in a wide range of cancers, including:

Hematological Malignancies: Allogeneic CAR T-cell therapies have shown significant promise in treating relapsed/refractory leukemias and lymphomas. Several products have received regulatory approval.
Solid Tumors: The application of allogeneic T cell therapies to solid tumors remains a significant area of active research. Challenges include the heterogeneous nature of solid tumors and the difficulty in targeting tumor-specific antigens without causing significant toxicity.

5. Future Directions in Allogeneic T Cell Therapy

The future of allogeneic T cell therapy is bright, with ongoing research focusing on:

Development of Universal CAR T Cells: The goal is to create "off-the-shelf" CAR T cells that can be used in any patient, regardless of their HLA type.
Improved Target Antigen Selection: Identifying and targeting tumor-specific antigens that are less likely to be expressed on healthy tissues is crucial for improving safety and efficacy.
Combination Therapies: Combining allogeneic T cell therapy with other immunotherapies, such as checkpoint inhibitors, or with targeted therapies, may further enhance anti-tumor responses.
Personalized Allogeneic T Cell Therapies: Tailoring allogeneic T cell therapies to individual patients based on their unique tumor characteristics and immune profiles may lead to improved outcomes.

6. Conclusion

Allogeneic T cell therapy represents a transformative approach to cancer treatment. While challenges remain, the ongoing advancements in T cell engineering, target antigen identification, and GvHD mitigation strategies promise to significantly improve the safety and efficacy of these therapies. The potential to provide an "off-the-shelf" treatment option for a broad range of patients makes allogeneic T cell therapy a vital area of research with the potential to revolutionize cancer care.

FAQs

1. What is the difference between allogeneic and autologous T cell therapy? Allogeneic T cell therapy uses donor T cells, while autologous therapy uses a patient's own T cells.

1. What are the potential side effects of allogeneic T cell therapy? The most significant side effect is graft-versus-host disease (GvHD). Other potential side effects include cytokine release syndrome (CRS) and neurotoxicity.

1. How is allogeneic T cell therapy administered? The process typically involves collecting donor T cells, engineering them in the laboratory (if necessary), expanding them in culture, and then infusing them into the patient.

1. What types of cancer are currently being treated with allogeneic T cell therapy? Allogeneic T cell therapies are being investigated for various cancers, particularly hematological malignancies.

1. What are the long-term effects of allogeneic T cell therapy? Long-term effects are still being studied, but potential issues include GvHD, immune reconstitution, and the development of secondary malignancies.

1. What is the cost of allogeneic T cell therapy? The cost is currently high due to the complexity of manufacturing these therapies.

1. What are the current regulatory approvals for allogeneic T cell therapies? Several allogeneic CAR T-cell therapies have received regulatory approval in various countries. However, the approval landscape is constantly evolving.

1. How is GvHD prevented or managed in allogeneic T cell therapy? GvHD is prevented or managed through careful donor selection, immunosuppressive medications, and novel T cell engineering strategies.

1. What is the future outlook for allogeneic T cell therapy? The outlook is promising, with significant ongoing research to improve safety, efficacy, and accessibility.

Related Articles

1. "Engineering Allogeneic CAR T Cells for Cancer Therapy": This article reviews the various engineering strategies used to improve the safety and efficacy of allogeneic CAR T cells.

1. "Overcoming Graft-versus-Host Disease in Allogeneic T Cell Therapy": This article focuses on the challenges and advancements in mitigating GvHD in allogeneic T cell therapy.

1. "Allogeneic T Cell Therapy for Leukemia: A Review of Clinical Trials": This article provides a comprehensive overview of the clinical trial data on the use of allogeneic T cell therapy for leukemia.

1. "The Role of CRISPR-Cas9 Gene Editing in Allogeneic T Cell Therapy": This article explores the application of CRISPR technology in engineering safer and more effective allogeneic T cells.

1. "Manufacturing and Quality Control of Allogeneic CAR T Cells": This article examines the intricacies of manufacturing allogeneic CAR T cells for clinical use.

1. "Immunological Considerations in Allogeneic T Cell Therapy": This article delves into the complex immune responses associated with allogeneic T cell therapy.

1. "Preclinical Models for Evaluating Allogeneic T Cell Therapy": This article discusses the various preclinical models used to assess the efficacy and safety of allogeneic T cell therapies.

1. "Economic Considerations of Allogeneic T Cell Therapy": This article analyzes the cost-effectiveness of allogeneic T cell therapy in comparison with other cancer treatments.

1. "The Future of Off-the-Shelf Allogeneic T Cell Therapies": This article looks towards the potential for readily available, "off-the-shelf" allogeneic T cell therapies.

 allogeneic t cell therapy: Haploidentical Transplantation Stefan O. Ciurea, Rupert Handgretinger, 2018-05-03 In this book, world-renowned experts in the field express well-reasoned opinions on a range of issues and controversies relating to haploidentical transplantation with the aim of providing practicing hematologists with clinically relevant and readily applicable information. Among the areas covered are graft manipulation and methods to control T-cell alloreactivity, the nature of the ideal graft and donor, haploidentical transplantation in pediatric and adult patients with malignant and nonmalignant diseases, immunologic reconstitution following transplantation, complications, and the prevention and treatment of relapse post transplantation. Attention is drawn to the implications of high-impact clinical trials whenever such trials are available. The readily

intelligible text is complemented by numerous helpful tables, algorithms, and figures. The book will provide practical support for hematologists and transplant physicians as they attempt to provide optimal care in this exciting but increasingly complex medical specialty.

allogeneic t cell therapy: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers' knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers' knowledge and practice skills.

allogeneic t cell therapy: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.

allogeneic t cell therapy: The European Blood and Marrow Transplantation Textbook for Nurses Michelle Kenyon, Aleksandra Babic, 2018-03-14 This book is open access under a CC BY 4.0 license. This textbook, endorsed by the European Society for Blood and Marrow Transplantation (EBMT), provides adult and paediatric nurses with a full and informative guide covering all aspects of transplant nursing, from basic principles to advanced concepts. It takes the reader on a journey through the history of transplant nursing, including essential and progressive elements to help nurses improve their knowledge and benefit the patient experience, as well as a comprehensive introduction to research and auditing methods. This new volume specifically intended for nurses, complements the ESH-EBMT reference title, a popular educational resource originally developed in 2003 for physicians to accompany an annual training course also serving as an educational tool in its own right. This title is designed to develop the knowledge of nurses in transplantation. It is the first book of its kind specifically targeted at nurses in this specialist field and acknowledges the valuable contribution that nursing makes in this area. This volume presents information that is essential for the education of nurses new to transplantation, while also offering a valuable resource for more experienced nurses who wish to update their knowledge.

allogeneic t cell therapy: Regenerative Biology and Medicine David L. Stocum, 2012-06-07 Regenerative Biology and Medicine, Second Edition — Winner of a 2013 Highly Commended BMA Medical Book Award for Medicine — discusses the fundamentals of regenerative biology and medicine. It provides a comprehensive overview, which integrates old and new data into an ever-clearer global picture. The book is organized into three parts. Part I discusses the mechanisms and the basic biology of regeneration, while Part II deals with the strategies of regenerative medicine developed for restoring tissue, organ, and appendage structures. Part III reflects on the achievements of regenerative biology and medicine; future challenges; bioethical issues that need to be addressed; and the most promising developments in regenerative medicine. The book is designed for multiple audiences: undergraduate students, graduate students, medical students and postdoctoral fellows, and research investigators interested in an overall synthesis of this field. It will also appeal to investigators from fields not directly related to regenerative biology and medicine, such as chemistry, informatics, computer science, mathematics, physics, and engineering. - Highly

Commended 2013 BMA Medical Book Award for Medicine - Includes coverage of skin, hair, teeth, cornea, and central neural tissues - Provides description of regenetive medicine in digestive, respiratory, urogenital, musculoskeletal, and cardiovascular systems - Includes amphibians as powerful research models with discussion of appendage regeneration in amphibians and mammals

allogeneic t cell therapy: Non-Myeloablative Allogeneic Transplantation Asad Bashey, Edward D. Ball, 2002-02-28 Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years. This approach uses non-cytotoxic or reduced-intensity cytotoxic therapy to prepare patients for allografting of hematopoietic stem cells and lymphocytes. It has the potential to deliver the potent anti-tumor immunotherapy and bone marrow replacement capacity of allogeneic stem cell transplantation to patients with reduced treatment-related morbidity and mortality. It may also enable allogeneic transplantation in patients who would be considered ineligible for conventional transplants because of co-morbidity or advanced age. However, this approach may necessitate more careful monitoring of post-transplant chimerism and malignant disease-status than is usual with conventional allografting. There is also controversy regarding the best preparative regimen and graft-versus-host disease prophylaxis to use.

allogeneic t cell therapy: *Progenitor and Stem Cell Technologies and Therapies* Anthony Atala, 2012-03-15 Progenitor and stem cells have the ability to renew themselves and change into a variety of specialised types, making them ideal materials for therapy and regenerative medicine. Progenitor and stem cell technologies and therapies reviews the range of progenitor and stem cells available and their therapeutic application.Part one reviews basic principles for the culture of stem cells before discussing technologies for particular cell types. These include human embryonic, induced pluripotent, amniotic and placental, cord and multipotent stem cells. Part two discusses wider issues such as intellectual property, regulation and commercialisation of stem cell technologies and therapies. The final part of the book considers the therapeutic use of stem and progenitor cells. Chapters review the use of adipose tissue-derived stem cells, umbilical cord blood (UCB) stem cells, bone marrow, auditory and oral cavity stem cells. Other chapters cover the use of stem cells in therapies in various clinical areas, including lung, cartilage, urologic, nerve and cardiac repair.With its distinguished editor and international team of contributors, Progenitor and stem cell technologies and therapies is a standard reference for both those researching in cell and tissue biology and engineering as well as medical practitioners investigating the therapeutic use of this important technology. - Reviews the range of progenitor and stem cells available and outlines their therapeutic application - Examines the basic principles for the culture of stem cells before discussing technologies for particular cell types, including human embryonic, induced pluripotent, amniotic and placental, cord and multipotent stem cells - Includes a discussion of wider issues such as intellectual property, regulation and commercialisation of stem cell technologies and therapies

allogeneic t cell therapy: Textbook on Scar Management Luc Téot, Thomas A. Mustoe, Esther Middelkoop, Gerd G. Gauglitz, 2020-12-07 This text book is open access under a CC BY 4.0 license. Written by a group of international experts in the field and the result of over ten years of collaboration, it allows students and readers to gain to gain a detailed understanding of scar and wound treatment – a topic still dispersed among various disciplines. The content is divided into three parts for easy reference. The first part focuses on the fundamentals of scar management, including assessment and evaluation procedures, classification, tools for accurate measurement of all scar-related elements (volume density, color, vascularization), descriptions of the different evaluation scales. It also features chapters on the best practices in electronic-file storage for clinical reevaluation and telemedicine procedures for safe remote evaluation. The second section offers a comprehensive review of treatment and evidence-based technologies, presenting a consensus of the various available guidelines (silicone, surgery, chemical injections, mechanical tools for scar stabilization, lasers). The third part evaluates the full range of emerging technologies offered to physicians as alternative or complementary solutions for wound healing (mechanical, chemical,

anti-proliferation). Textbook on Scar Management will appeal to trainees, fellows, residents and physicians dealing with scar management in plastic surgery, dermatology, surgery and oncology, as well as to nurses and general practitioners

allogeneic t cell therapy: Developing Costimulatory Molecules for Immunotherapy of Diseases Manzoor Ahmad Mir, 2015-05-25 Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation. The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases. - Highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy - Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families - Targets new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases

allogeneic t cell therapy: Translational Regenerative Medicine Anthony Atala, Julie Allickson, 2014-12-01 Translational Regenerative Medicine is a reference book that outlines the life cycle for effective implementation of discoveries in the dynamic field of regenerative medicine. By addressing science, technology, development, regulatory, manufacturing, intellectual property, investment, financial, and clinical aspects of the field, this work takes a holistic look at the translation of science and disseminates knowledge for practical use of regenerative medicine tools, therapeutics, and diagnostics. Incorporating contributions from leaders in the fields of translational science across academia, industry, and government, this book establishes a more fluid transition for rapid translation of research to enhance human health and well-being. - Provides formulaic coverage of the landscape, process development, manufacturing, challenges, evaluation, and regulatory aspects of the most promising regenerative medicine clinical applications - Covers clinical aspects of regenerative medicine related to skin, cartilage, tendons, ligaments, joints, bone, fat, muscle, vascular system, hematopoietic /immune system, peripheral nerve, central nervous system, endocrine system, ophthalmic system, auditory system, oral system, respiratory system, cardiac system, renal system, hepatic system, gastrointestinal system, genitourinary system - Identifies effective, proven tools and metrics to identify and pursue clinical and commercial regenerative medicine

allogeneic t cell therapy: Cancer Immunology and Immunotherapy Mansoor M. Amiji, Lara Scheherazade Milane, 2021-08-18 Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer

biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. - Comprehensive treaty covering all aspects of immuno-oncology (IO) - Novel strategies for delivery of IO therapeutics and vaccines - Forecasting on the future of nanotechnology and drug delivery for IO

allogeneic t cell therapy: Allogeneic Stem Cell Transplantation Hillard M. Lazarus, Mary J. Laughlin, 2010-03-02 Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Some of the most respected clinicians and scientists in this discipline have responded to the recent advances in the field by providing state-of-the-art discussions addressing these topics in the second edition. The text covers the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. Comprehensive and up-to-date, Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Second Edition offers concise advice on today's best clinical practice and will be of significant benefit to all clinicians and researchers in allogeneic HSC transplantation.

allogeneic t cell therapy: The Comprehensive Cancer Center Mahmoud Aljurf, Navneet S. Majhail, Mickey B.C. Koh, Mohamed A. Kharfan-Dabaja, Nelson J. Chao, 2021-10-28 This open access book provides a valuable resource for hospitals, institutions, and health authorities worldwide in their plans to set up and develop comprehensive cancer care centers. The development and implementation of a comprehensive cancer program allows for a systematic approach to evidence-based strategies of prevention, early detection, diagnosis, treatment, and palliation. Comprehensive cancer programs also provide a nexus for the running of clinical trials and implementation of novel cancer therapies with the overall aim of optimizing comprehensive and holistic care of cancer patients and providing them with the best opportunity to improve quality of life and overall survival. This book's self-contained chapter format aims to reinforce the critical importance of comprehensive cancer care centers while providing a practical guide for the essential components needed to achieve them, such as operational considerations, guidelines for best clinical inpatient and outpatient care, and research and quality management structures. Intended to be wide-ranging and applicable at a global level for both high and low income countries, this book is also instructive for regions with limited resources. The Comprehensive Cancer Center: Development, Integration, and Implementation is an essential resource for oncology physicians including hematologists, medical oncologists, radiation oncologists, surgical oncologists, and oncology nurses as well as hospitals, health departments, university authorities, governments and legislators.

allogeneic t cell therapy: Regulatory Aspects of Gene Therapy and Cell Therapy Products Maria Cristina Galli, Mercedes Serabian, 2015-09-15 This book discusses the different regulatory pathways for gene therapy (GT) and cell therapy (CT) medicinal products implemented by national and international bodies throughout the world (e.g. North and South America, Europe, and Asia). Each chapter, authored by experts from various regulatory bodies throughout the international community, walks the reader through the applications of nonclinical research to translational clinical research to licensure for these innovative products. More specifically, each chapter offers insights into fundamental considerations that are essential for developers of CT and GT products, in the areas of product manufacturing, pharmacology and toxicology, and clinical trial design, as well as pertinent must-know guidelines and regulations. Regulatory Aspects of Gene Therapy and Cell Therapy Products: A Global Perspective is part of the American Society of Gene and Cell Therapy sub-series of the highly successful Advances in Experimental Medicine and Biology series. It is essential reading for graduate students, clinicians, and researchers interested in gene and cell therapy and the regulation of pharmaceuticals.

allogeneic t cell therapy: The Peripheral T-Cell Lymphomas Owen A. O'Connor, Won Seog Kim, Pier L. Zinzani, 2021-06-01 THE PERIPHERAL T-CELL LYMPHOMAS Provides a comprehensive look at Peripheral T-Cell lymphomas, including the group’s unique geographic

distribution, underlying genetics, and novel treatments Peripheral T-Cell lymphomas (PTCL) are a diverse group of lymphoid malignancies that develop from mature T cells and natural killer (NK) cells. PTCL represent 10-15% of all cases of non-Hodgkin lymphoma in the US, and up to 20-25% of cases in South America, Asia, and other regions around the world. The role of different etiologic factors and the variation of geographic distribution makes PTCL one of the most difficult types of cancer to understand and treat. For the first time in a single volume, The Peripheral T-Cell Lymphomas presents a comprehensive survey of this complex and rare group of blood cancers. Featuring contributions from an international team of leading authorities in the various aspects of PTCL, this authoritative text covers biology, epidemiology, classification, approved and emerging drugs, molecular genetics, and more. Detailed clinical chapters address diagnosis, prognosis, and treatment of each of the major PTCL subtypes identified in the 2018 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. This much-needed resource: Covers the biological basis, epidemiology, classification, and treatment of PTCL Discusses the future of the field, including global collaboration efforts and novel approaches to PCTL Explores the role of biologics in PTCL and autologous and allogeneic stem-cell transplantation Offers new insights on molecular pathogenesis, innovative therapeutics, and novel drug combinations Features contributions from the Chairs The T-Cell Lymphoma Forum: the world's largest meeting focused on PTCL Reflecting the unique epidemiology and genetic diversity of the PTCL, The Peripheral T-Cell Lymphomas is an indispensable source of data, insight, and references for the medical community, particularly oncologists and hematologists in both training and practice.

allogeneic t cell therapy: *Quality Management and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy* Mahmoud Aljurf, John A. Snowden, Patrick Hayden, Kim H. Orchard, Eoin McGrath, 2021-02-19 This open access book provides a concise yet comprehensive overview on how to build a quality management program for hematopoietic stem cell transplantation (HSCT) and cellular therapy. The text reviews all the essential steps and elements necessary for establishing a quality management program and achieving accreditation in HSCT and cellular therapy. Specific areas of focus include document development and implementation, audits and validation, performance measurement, writing a quality management plan, the accreditation process, data management, and maintaining a quality management program. Written by experts in the field, Quality Management and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy: A Practical Guide is a valuable resource for physicians, healthcare professionals, and laboratory staff involved in the creation and maintenance of a state-of-the-art HSCT and cellular therapy program.

allogeneic t cell therapy: EBMT HANDBOOK , 2025

allogeneic t cell therapy: Exploring Novel Clinical Trial Designs for Gene-Based Therapies National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Regenerative Medicine, 2020-08-27 Recognizing the potential design complexities and ethical issues associated with clinical trials for gene therapies, the Forum on Regenerative Medicine of the National Academies of Sciences, Engineering, and Medicine held a 1-day workshop in Washington, DC, on November 13, 2019. Speakers at the workshop discussed patient recruitment and selection for gene-based clinical trials, explored how the safety of new therapies is assessed, reviewed the challenges involving dose escalation, and spoke about ethical issues such as informed consent and the role of clinicians in recommending trials as options to their patients. The workshop also included discussions of topics related to gene therapies in the context of other available and potentially curative treatments, such as bone marrow transplantation for hemoglobinopathies. This publication summarizes the presentation and discussion of the workshop.

allogeneic t cell therapy: Immunopharmacogenomics Yusuke Nakamura, 2015-09-18 This book proposes immunogenomics, or immunopharmacogenomics, as the next-generation big science to uncover the role that the immune system plays in the pathogenesis of many diseases, by summarizing the importance of the deep sequencing of T-cell and B-cell receptors.

Immunogenomics/immunopharmacogenomics, a genetic characterization of the immune system made possible by next-generation sequencing (NGS), will be important for the further understanding of the pathogenesis of various disease conditions. Abnormal immune responses in the body lead to development of autoimmune diseases and food allergies. Rejection of recipient cells and tissues, as well as severe immune reactions to donor cells, is also the result of uncontrolled immune responses in the recipient body. There have been many reports indicating that activated immune responses caused by the interaction of drugs and HLA are present in drug-induced skin hypersensitivity and liver toxicity. The importance of the host immune responses has been recognized in cancer treatments, not only for immunotherapy but also for cytotoxic agents and molecular targeted drugs. Hence, characterization of the T-cell receptor and B-cell receptor repertoire by means of NGS deep sequencing will ultimately make possible the identification of the molecular mechanisms that underlie various diseases and drug responses. In addition, this approach may contribute to the identification of antigens associated with the onset or progression of autoimmune diseases as well as food allergies. Although the germline alterations and somatic mutations have been extensively analyzed, changes or alterations of the immune responses during the course of various disease conditions or during various treatments have not been analyzed. It is also clear that computational analyses to draw meaningful inferences of functional recognition receptors on the immune cells remain a huge challenge.

allogeneic t cell therapy: Blood and Marrow Transplant Handbook Richard T. Maziarz, Susan Schubach Slater, 2015-04-20 This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook includes indications for transplantation and donor selection, treatment guidelines for addressing complications during and after transplant, and recommendations for long-term follow up care. Concise, comprehensive, and easy-to-use, Blood and Marrow Transplant Handbook, 2nd Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers who care for transplant patients, and also residents, fellows, and other trainees.

allogeneic t cell therapy: Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases Richard K. Burt, Dominique Farge, Milton A. Ruiz, Riccardo Saccardi, John A. Snowden, 2021-11-17 This book summarizes the global progress in medical and scientific research toward converting traditionally chronic autoimmune diseases into a drug-free reversible illness using hematopoietic stem cell transplantation (HSCT) and other cellular therapies such as T regulatory cells (Treg), mesenchymal stromal/stem cells, and chimeric antigen receptor T (CAR T) cells in order to reintroduce sustained immune tolerance. This title provides information on different types of stem cells and immune cells; post-transplant immune regeneration; cellular regulatory requirements; ethical and economic considerations; and the advantages and disadvantages of HSCT in the treatment of a variety of autoimmune diseases versus current conventional treatments. Arranged by disease, the text provides a comprehensive guide to HSCT for all types of autoimmune/immune disorders including monogenetic autoimmune diseases; autoimmune aplastic anemia; neurologic immune diseases including multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, neuromyelitis optica, and stiff person syndrome; rheumatologic diseases such as systemic sclerosis and systemic lupus erythematosus; dermatologic diseases such as pemphigus; gastrointestinal disorders such as Crohn’s disease and celiac disease; and immune-mediated endocrinologic disease type I diabetes mellitus. Guidance is provided on the transplantation technique, cell collection and processing, conditioning regimens, infections, and early and late complications. Key Features Outlines therapies and techniques for HSCT for autoimmune diseases Discusses the advantages of HSCT over conventional therapies Reviews the entire process of stem cell therapy from harvest and ethics to indications, efficacy, and regulatory oversight

allogeneic t cell therapy: Epstein Barr Virus Volume 2 Christian Münz, 2015-10-01 Epstein Barr virus (EBV) was discovered as the first human tumor virus around 50 years ago. Since its discovery in Burkitt's lymphoma it has been associated with various other malignancies, infectious mononucleosis and even autoimmune diseases. The two book volumes on EBV summarize the first 50 years of research on this tumor virus, starting with historical perspectives on discovery, oncogenicity and immune control, reviewing the role that the virus plays in the various associated diseases and concluding with a discussion on how the immune system keeps persistent EBV infection under control in healthy EBV carriers and can be used to treat EBV associated diseases. The respective 32 chapters are written by international experts from three continents for health care providers, biomedical researchers and patients that are affected by EBV. The assembled knowledge should help to understand EBV associated diseases better and to develop EBV specific vaccination in the near future.

allogeneic t cell therapy: Infectious Complications in Transplant Recipients Nina Singh, José M. Aguado, 2000-12-31 Infectious Complications in Transplant Patients has been uniquely designed and formatted to address issues and trends pertaining to pathogens deemed important in critically ill transplant patients. The chapters have been carefully selected so as to direct the focus of the book towards current approaches to controversial, emerging or topical problems in these patients. Each chapter has been authored by a North American and a European specialist. This format serves to impart an added dimension reflective of the diversity of opinions and practices pertaining to unresolved or controversial issues. The authors are recognized experts in their respective fields.

allogeneic t cell therapy: Tertiary Lymphoid Organs (TLOs): Powerhouses of Disease Immunity Changjun Yin, Andreas J.R. Habenicht, Sarajo Mohanta, Pasquale Maffia, 2017-05-22 The immune system employs TLOs to elicit highly localized and forceful responses to unresolvable peripheral tissue inflammation. Current data indicate that TLOs are protective but they may also lead to collateral tissue injury and serve as nesting places to generate autoreactive lymphocytes. A better comprehension of these powerhouses of disease immunity will likely facilitate development to unprecedented and specific therapies to fight chronic inflammatory diseases.

allogeneic t cell therapy: *Brain Tumor Imaging* Elke Hattingen, Ulrich Pilatus, 2015-09-02 This book describes the basics, the challenges and the limitations of state of the art brain tumor imaging and examines in detail its impact on diagnosis and treatment monitoring. It opens with an introduction to the clinically relevant physical principles of brain imaging. Since MR methodology plays a crucial role in brain imaging, the fundamental aspects of MR spectroscopy, MR perfusion and diffusion-weighted MR methods are described, focusing on the specific demands of brain tumor imaging. The potential and the limits of new imaging methodology are carefully addressed and compared to conventional MR imaging. In the main part of the book, the most important imaging criteria for the differential diagnosis of solid and necrotic brain tumors are delineated and illustrated in examples. A closing section is devoted to the use of MR methods for the monitoring of brain tumor therapy. The book is intended for radiologists, neurologists, neurosurgeons, oncologists and other scientists in the biomedical field with an interest in neuro-oncology.

allogeneic t cell therapy: *Guide to Immunotherapy* Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2018-10

allogeneic t cell therapy: Basics of Chimeric Antigen Receptor (CAR) Immunotherapy Mumtaz Y. Balkhi, 2019-07-31 Basics of Chimeric Antigen Receptor (CAR) Immunotherapy presents the latest on how T cell adoptive immunotherapy has progressed in its ultimate goal of curing metastatic malignant cancers. Recent clinical data obtained with checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy has been especially promising, thus generating renewed hope that we may be on the verge of finally curing cancer. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application of checkpoint receptor inhibitory drugs and CAR-Therapy that has seen unprecedented interest in the immunotherapy field. - Presents the first book to provide a basic understanding of chimeric antigen receptor (CARs) design, production and clinical application protocols - Provides unique authority as

the editor has worked directly with CARs - Discusses the challenges encountered in actual clinical trials and how these challenges can be overcome - Includes a full chapter on various challenges researchers should expect to encounter in the CAR-therapy field

allogeneic t cell therapy: Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation Gerard Socie, Robert Zeiser, Bruce R. Blazar, 2018-11-22 Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation: Models in Discovery and Translation, Second Edition once again provides clinical and scientific researchers with a deep understanding of the current research in this field and the implications for translational practice. By providing an overview of the immune biology of HSCT, an explanation of immune rejection, and detail on antigens and their role in HSCT success, this book embraces biologists and clinicians who need a broad view of the deeply complex processes involved. It then moves on to discuss the immunobiology mechanisms that influence graft-versus-host disease (GVHD), graft-versus-leukemia effect, and transplantation success. Using illustrative figures, highlighting key issues, describing recent successes, and discussing unanswered questions, this book sums up the current state of HSCT to enhance the prospects for the future. The second edition is fully revised and includes new chapters on microbiome, metabolism, kinase targets, micro-RNA and mRNA regulatory mechanisms, signaling pathways in GVHD, innate lymphoid system development, recovery and function in GVHD, genetically engineered T-cell therapies, immune system engagers for GVHD and graft-versus-tumor, and hematopoietic cell transplant for tolerance induction in solid organ grafts. - Brings together perspectives from leading laboratories and clinical research groups to highlight advances from bench to the bedside - Guides readers through the caveats that must be considered when drawing conclusions from studies with animal models before correlating to clinical allogeneic hematopoietic stem cell transplantation (HSCT) scenarios - Categorizes the published advances in various aspects of immune biology of allogeneic HSCT to illustrate opportunities for clinical applications

allogeneic t cell therapy: Gene Therapy of Autoimmune Disease Gerald J. Prud'homme, 2005-07-13 Autoimmune diseases are diverse and responsible for considerable morbidity. Their etiology remains largely unknown, and current therapy with anti-inflammatory drugs is prone to adverse effects, and rarely curative. New therapies with anti-cytokine antibodies or receptors are promising, but require frequent administration of expensive protein drugs. Gene Therapy of Autoimmune Diseases comprehensively reviews research in gene therapy for autoimmune diseases with viral or non-viral vectors. Gene therapy offers the possibility of long-term, continuous delivery of a wide variety of immunosuppressive, anti-inflammatory, or tolerance-inducing agents. Moreover, highly specific genetically modified cells can be produced. This book discusses the most promising avenues in this exciting new field.

allogeneic t cell therapy: Drug Resistance in Leukemia & Gert-Jan L. Kaspers, 1993-01-01 The last ten years have seen the publication of a vast amount of data regarding cellular resistance to drugs in cancer cells. Recent studies have demonstrated that drug resistance assays appear to be predictive of clinical response and suggest that clinicians should now be considering the potential applications of these assays in the treatment of patients with hematological neoplasms. This collection of papers from the International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma, Amsterdam, 1992, provides a state-of-the-art discussion on drug resistance assays and their role in the design and individualization of treatment protocols.

allogeneic t cell therapy: Mesenchymal Stem Cell Therapy Lucas G. Chase, Mohan C Vemuri, 2012-12-12 Over the past decade, significant efforts have been made to develop stem cell-based therapies for difficult to treat diseases. Multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSCs), appear to hold great promise in regards to a regenerative cell-based therapy for the treatment of these diseases. Currently, more than 200 clinical trials are underway worldwide exploring the use of MSCs for the treatment of a wide range of disorders including bone, cartilage and tendon damage, myocardial infarction, graft-versus-host disease, Crohn’s disease, diabetes, multiple sclerosis, critical limb ischemia and many others. MSCs were first identified by Friendenstein and colleagues as an adherent stromal cell population within

the bone marrow with the ability to form clonogenic colonies in vitro. In regards to the basic biology associated with MSCs, there has been tremendous progress towards understanding this cell population’s phenotype and function from a range of tissue sources. Despite enormous progress and an overall increased understanding of MSCs at the molecular and cellular level, several critical questions remain to be answered in regards to the use of these cells in therapeutic applications. Clinically, both autologous and allogenic approaches for the transplantation of MSCs are being explored. Several of the processing steps needed for the clinical application of MSCs, including isolation from various tissues, scalable in vitro expansion, cell banking, dose preparation, quality control parameters, delivery methods and numerous others are being extensively studied. Despite a significant number of ongoing clinical trials, none of the current therapeutic approaches have, at this point, become a standard of care treatment. Although exceptionally promising, the clinical translation of MSC-based therapies is still a work in progress. The extensive number of ongoing clinical trials is expected to provide a clearer path forward for the realization and implementation of MSCs in regenerative medicine. Towards this end, reviews of current clinical trial results and discussions of relevant topics association with the clinical application of MSCs are compiled in this book from some of the leading researchers in this exciting and rapidly advancing field. Although not absolutely all-inclusive, we hope the chapters within this book can promote and enable a better understanding of the translation of MSCs from bench-to-bedside and inspire researchers to further explore this promising and quickly evolving field.

allogeneic t cell therapy: *Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice* MiKaela M. Olsen, Kristine B. LeFebvre, Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2022 Oncology nursing is a unique specialty that requires continuous learning to stay up to date on cancer pathophysiology, cutting-edge drugs, and the evidence-based management of cancer and cancer treatment-related toxicities. The Oncology Nursing Society's (ONS's) second edition of Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice provides nurses with the tools to understand how medications are used in cancer treatment, the effect of medication-related toxicities, and evidence-based recommendations to manage and treat these toxicities. This edition features many new cancer therapies approved since the 2019 publication. Each drug is categorized as chemotherapy, hormone, targeted, or immunotherapy agents. Extensive drug tables in the book provide nurses with tips for managing patients receiving these drugs. The expansion of oral antineoplastic therapies, alone or in combination with infusion therapy, requires that nurses review a patient's complete cancer treatment plan and consider the side effects, toxicities, and adherence to oral drugs to ensure patient tolerance and efficacy. This second edition has seen content expanded on the topic of genomics as we move forward in the world of personalized oncology. Health equity is approached with information discussing financial distress, cultural disparities, and health literacy. The latest guidelines and recommendations for treatment, symptom management, and survivorship have been integrated into this new text. This edition features a QR code, provided with the purchase of this book, to download quarterly drug updates. You will see new evidence related to many aspects of cancer nursing care incorporated into this edition, such as hypersensitivity response, safe handling of hazardous drugs, and more. The editors want to thank all of the contributors to this edition who worked tirelessly, despite a pandemic, to make this new edition a reality. This work builds on the knowledge of many generations of oncology nurses and has been used nationally and internationally to guide oncology nursing practice. We are proud to continue to serve oncology nurses worldwide with an essential resource to guide their practice--

allogeneic t cell therapy: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established

researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field.

allogeneic t cell therapy: Cell and Gene Therapies Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard, 2018-11-27 In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee.

allogeneic t cell therapy: *Perinatal Stem Cells* Anthony Atala, Kyle J. Cetrulo, Rouzbeh R. Taghizadeh, Curtis L Cetrulo, Sean Murphy, 2018-06-14 Perinatal Stem Cells provides researchers and clinicians with a comprehensive description of the current clinical and pre-clinical applications of stem cells derived from perinatal sources, such as amniotic fluid, placenta and placental membranes, the umbilical cord and Wharton's jelly. It's compiled by leading experts in the field, offering readers detailed insights into sources of perinatal stem cells and their potential for disease treatment. Therapeutic applications of perinatal stem cells include the treatment of in utero and pregnancy related diseases, cardiac disease, liver disease, pulmonary disease, inflammatory diseases, for hematopoietic regeneration, and for neural protection after stroke or traumatic brain injury. In addition, the rapid advance in clinical translation and commercialization of perinatal stem cell therapies is highlighted in a section on Clinical and Industry Perspective which provides insight into the new opportunities and challenges involved in this novel and exciting industry. - Explores current clinical and pre-clinical application of stem cells derived from perinatal sources - Offers detailed insight into sources of perinatal stem cells and their potential for disease treatment - Discusses progress in the manufacturing, banking and clinical translation of perinatal stem cells - Edited by a world-renowned team to present a complete story of the development and promise of perinatal stem cells

allogeneic t cell therapy: Cutaneous T-Cell Lymphoma Herschel S. Zackheim, 2004-10-28 Cutaneous T-cell lymphoma (CTCL) is a general term for many lymphomas of the skin including mycosis Fungoides and Sezary syndrome. This book presents the state of the art in CTCL epidemiology, clinical features, pathology, immunochemistry, diagnostic molecular techniques, staging and prognosis, and treatment. Edited by one of the leading experts in the disease, Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sezary Syndrome provides comprehensive coverage of the disease and presents techniques for diagnosis and state-of-the-art treatment modalities, such as ultraviolet light, steroids, and topical chemotherapeutics.

allogeneic t cell therapy: *Immunotherapy of Hepatocellular Carcinoma* Tim F. Greten, 2018-08-22 In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the

United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.

allogeneic t cell therapy: Moving Towards Allogeneic Cellular Therapies: Opportunities and Challenges Federico Simonetta, Alice Bertaina, Peter Bader, 2022-08-09

allogeneic t cell therapy: Extracellular Matrix-derived Implants in Clinical Medicine Daniel Mooradian, 2016-05-23 Extracellular Matrix-Derived Implants in Clinical Medicine comprehensively covers the emergence of tissue engineering and regenerative medicine over the past few decades, along with discussions of continuous funding and research. The book provides a state-of-the-art review of this increasingly important technology and how it is translating from bench to bedside. Part One of the book looks at the historical use of human and animal tissues, focusing on the main application areas, including cardiovascular, hard and soft tissue engineering, and neurological, while Part Two examines the challenges in harvesting, processing, and manufacturing of extracellular matrices, with a final section reviewing the international regulatory environment and economics of tissue-based products.

allogeneic t cell therapy: *Developments in T Cell Based Cancer Immunotherapies* Paolo A. Ascierto, David F. Stroncek, Ena Wang, 2015-11-26 This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.

Additional Resources

Allogeneic CAR-T Therapy Technologies: Has the Promise Been ...
Among the most promising options, T-cells engineered to express chimeric antigen receptors (CAR) aim to strengthen the power of T-cells to recognize and eliminate tumor cells in a human ...

‘Off-the-shelf’ allogeneic CAR T cells: development and ...
In this Review, we analyse the different sources of T cells for optimal allogeneic CAR-T cell therapy and describe the different technological approaches, mainly based on gene editing, to produce ...

Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT ...
Apr 24, 2024 · Our findings suggest that sequential CD7 CAR T-cell therapy and haploidentical HSCT is safe and effective, with remission and serious but reversible adverse events. This ...

Innovative Allogeneic CAR T Cell Therapy Trial Shows ...
Mar 27, 2025 · Houston Methodist has administered the novel treatment to seven patients as part of a first-of-its-kind, national, industry-sponsored Phase 1 clinical trial for patients with relapsed ...

'Off-the-shelf' allogeneic CAR T cells: development and ...

Jan 3, 2020 · In this Review, we analyse the different sources of T cells for optimal allogeneic CAR-T cell therapy and describe the different technological approaches, mainly based on gene editing,...

Allogeneic CAR T Cell Therapy: Potential and Challenges

Apr 29, 2025 · Allogeneic CAR T cell therapy uses genetically modified donor T cells to target malignant cells. These engineered cells carry a chimeric antigen receptor (CAR), a synthetic ...

Allogeneic CAR T cells: A new player in the field and the ...

Jun 4, 2025 · To overcome this limitation and poor T cell function, we pioneered the use of GD2-CART01 generated from allogeneic, donor-derived lymphocytes in 5 patients who received an ...

CYAD-101: An innovative non-gene edited allogeneic CAR-T ...

CYAD-101 is a novel, first-in-class, allogeneic NKG2D receptor-based CAR T-cell therapy (Figure 1). The allogeneic CYAD-101 CAR T-cell product uses a non-gene edited T-cell receptor ...

Cell Stem Cell Perspective - Cell Press

utilize alternative T cell sources, which include virus-speci c or T cell receptor-less allogeneic T cells, expanded lymphoid progenitors, and induced pluripotent stem cell (iPSC)-derived T ...

Donor Qualification and Procurement of Allogeneic Cellular

National Marrow Donor Program® (NMDP)/Be The Match® 30+ years of global leadership in cell therapy 121,000+ total cell transplants managed 36,000+ annual cell and blood shipments ...

a non-viral allogeneic T therapy with potent anti-for the ...

T SCM –The Ideal T Cell for Adoptive Immunotherapy •P-BCMA-101 –an autologous T SCM CAR-T %T SCM correlates with response in patients Gradual expansion of T SCM CAR-T ...

White Paper Cell and Gene Therapy Logistics Management

Logistics management is a key element of operationalizing cell and gene therapy (CAGT) trials. There are unique logistics requirements for autologous cell therapy modalities and allogeneic ...

Allogeneic Vγ9Vδ2 T-Cell Therapy Promotes Pulmonary

Inthe present study, we utilized allogeneic Vg9Vd2 T cells for the treatment of patients with MDR-TB who had signi cantly limited options in effective anti-TB drugs. We enrolled eight patients ...

Autologous, Allogeneic CAR T, and the New Frontiers of CAR ...

T cells, and the neurotoxicity effect detected have to be managed (3). Two autologous CAR T cell products are already on the market, Yescarta and Kymriah, for the treatment of some ...

Allogeneic anti-CD19 CAR-T cells induce remission in

safety and ef cacy of CAR-T cell therapy in B cell-mediated autoimmune diseases. 1–5 Allogeneic CAR-T cells, distinguished by their homogeneity, rapid availability, and potential for ...

CD3 engagement as a new strategy for allogeneic "off-the ...

effective, these strategies add more complex to allogeneic OTS CAR-T cell therapy. Meanwhile, like autologous CAR-T therapy, allogeneic OTS CAR-T cells have adverse effects such as ...

Breaking the mold: Unconventional T cells in cancer therapy

of 174 patients undergoing allogeneic he-matopoietic stem cell transplantation for hematologic malignancies demonstrated that higher levels of gd T cells and MAIT cells correlated with ...

CD3 engagement as a new strategy for allogeneic "off-the ...

effective, these strategies add more complex to allogeneic OTS CAR-T cell therapy. Meanwhile, like autologous CAR-T therapy, allogeneic OTS CAR-T cells have adverse effects such as ...

C THERAPY INSIGHTS - Thermo Fisher Scientific

neic T-cell therapies has the potential to make these cutting-edge therapies more accessible. Through the innovation of a novel medium formulated specifically for allogeneic T-cell therapy ...

Transplantation and Cellular Therapy - astctjournal.org
CAR-T therapy eventually succumb to relapse, regardless of CAR-T construct [3,4,7]. Therefore, there is a need to identify strategies to extend durability of remission following CAR-T therapy ...

Integration of a CD19 CAR into the TCR Alpha Chain Locus
CAR T product to be generated and made available, and any dif- culties encountered in the manufacturing of cells could prove to be devastating. The use of allogeneic CAR T cells ...

Toward "off-the-shelf" allogeneic CAR T cells - Wiley Online ...
unmodified, unselected, or unmanipulated allogeneic T cells. 20 In this Review, we will present the main approaches that are currently in development to deliver allogeneic T cell therapy and ...

Engineering Tolerance toward Allogeneic CAR-T Cells by
ure 4D). These data support the notion that masking from T cell recognition by K3 expression could effectively modulate allogeneic lymphocyte responses. K3 Expression Does Not Impair ...

Allogeneic CAR T Cells: An Alternative to Overcome ...
Challenges of CAR T Cell Therapy in Glioblastoma. Front. Immunol. 12:640082. doi: 10.3389/fimmu.2021.640082 ... Avoiding GVHD concentrates most efforts in allogeneic CAR ...

Regulatory Considerations for CAR T Cell Development - CASSS
CAR T Cell Development Kim Schultz, PhD US Food and Drug Administration - CBER ... Human Gene Therapy (GT) Products www.fda.gov "mediate their effects by transcription or translation ...

Higher risk of platelet engraftment failure and chronic ...
RECEPTOR T CELL THERAPY AND CHEMOTHERAPY CD7 CAR- T, achieving CR rates over 90%. 5–7 However, most remissions following CAR- T therapy are short, necessitating urgent ...

The state of cell and gene therapy in 2023 - Cell Press
Dec 12, 2023 · cell therapy programs in diseases as diverse as diabetes, heart failure, and multiple sclerosis. ... first-approved allogeneic T cell immunotherapy, and a continuation of ...

Abstract P1160 A CRISPR-edited allogeneic anti-CD19 CAR-T ...
Jun 3, 2024 · A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) for relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 ...

Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT
The new england journal of medicine n engl j med 390;16 nejm.org April 25, 2024 1467 The authors' affiliations are listed in the Appendix. Dr. Huang can be contacted at hunaghate u j z . deu . n ...

Immunosuppressant therapy averts rejection of allogeneic ...
may represent a barrier that limits the efficacy of allogeneic CAR-T cell therapy. Inactivation of the T cell receptor (TCR) in allogeneic CAR-T cells can prevent graft-versus-host disease ...

First-in-Human Data of ALLO-501 and ALLO-647 in Relapsed ...
May 11, 2020 · Host T-cell mediated rejection delayed with ALLO-647 (anti-CD52 mAb) Reduce GvHD with TCRa Knockout 2 TALEN® is a Cellectis gene editing technology Allogeneic CAR ...

Allogeneic stem cell transplants - Leukaemia Foundation
12 Allogeneic stem cell transplants Tissue typing 13 CAR T-cell therapy Chimeric antigen receptor (CAR) T-cell therapy, is an immunotherapy that uses your own immune cells (T-cells) to first ...

Trends in Biotechnology - Cell Press
Although allogeneic and in vivo cell therapies are being inves-tigated, they are not yet commercially available [4]. In the meantime, to realize ... Grover, P.et al. (2022) Chimeric ...

Cas-CLOVER is a novel high-fidelity nuclease for safe and
The use of T cells from healthy donors for allogeneic chimeric antigen receptor T (CAR-T) cell cancer therapy is attractive because healthy donor T cells can produce versatile off-the-shelf ...

2024 State of the Industry Briefing - Alliance for Regenerative ...

Jan 8, 2024 · of adoptive cell therapy for solid tumor (US) and first US approval of allogeneic T-cell therapy Additional therapies to treat hemophilia A, hemophilia B, and dystrophic ...

CAR-T Therapy - Morgan Stanley

Dec 31, 2024 · CAR-T cell therapy seeks to simplify this process by genetically engineering a patient's own cells to efficiently and effectively target and eliminate cancer. Doctors ... as ...

Viral protein Nef enables a step toward off-the-shelf CAR T ...

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune ... enhances allogeneic CAR T cell ...

CAR T-Cell Therapy - Indegene

bridge therapy Allogeneic CAR T-Cell Therapy • The T cells are derived from a healthy donor (unlike autologous CAR T-cell therapy) and the CAR T-cells are developed from a single ...

A Novel Strategy for Off-The-Shelf T Cell Therapy which ...

A Novel Strategy for Off-The-Shelf T Cell Therapy which Evades Host T Cell and NK Cell Rejection 63rd ASH Annual Meeting & Expositions, December 2021 CONCLUSIONS DATA ...

ADI-925: an allogeneic off-the-shelf Chimeric Adapter (CAd) ...

untransduced Vδ1 T cells before (Day 0) and after 5-day coculture with PLC/PRF/5 target cells. Each line represents a unique batch of effector cells. *p=0.043; ns=not significant. • ADI-925 is ...

Detection of chromosomal alteration after infusion of gene ...

allogeneic CAR T therapy made from healthy donor T cells holds great promise. In order to allow cells from an unrelated host to be used without causing graft-versus-host disease (GvHD), ...

ALLO647 for Lymphodepletion in the Allogeneic CAR T Cell ...

• Autologous CAR T cell therapy following lymphodepletion is associated with adverse events such as cytopenias ... (FC) and ALLO647 followed by administration of allogeneic CD19 CAR ...

Allogeneic CD19-targeted CAR-T therapy in refractory

Conclusions: In patients with severe and refractory SLE, allogeneic CAR-T cell therapy showed profound safety and clinical efficacyfor disease remission. Funding: 82320108010, 31821003, ...

Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit

T cell expansion and effector function, CAR T cells were co-cultured with AML target cell lines expressing varying levels of wild-type and/ or mutant FLT3 (Figure S2A), with fresh target cells ...

IMMUNICY-1: Targeting BCMA with CYAD-211 to Establish ...

IMMUNICY-1: Targeting BCMA with CYAD-211 to Establish Proof Of Concept of An shRNA-based Allogeneic CAR T-cell Therapy Platform A Samer Al-Homsi 1, S bastien Anguille 2, ...

Safety and efficacy of autologous and allogeneic humanized ...

CAR-T cell therapy for patients with relapsed/refractory B-ALL Fengmei Song , 1,2,3,4 Yongxian Hu,1,2,3,4 Yanlei Zhang,5 Mingming Zhang,1,2,3,4 ... patients treated with consolidation ...

Clinical development of allogeneic chimeric antigen receptor ...

CAR-T cell of CAR-T products cell have therapy, attracted and some price tags commercial of hundreds autologous of thou-sands of dollars, 14perhaps toxicity.comparable notably with ...

Cost analysis of vein-to-vein CAR T-cell therapy: automated ...

CAR T-cell therapy: automated manufacturing and supply chain Adriana G Lopes, Rob Noel & ... [5–7,11] or CAR-T allogeneic cell therapies [12,13]. Allogeneic manufacturing

Preclinical Evaluation of ALLO -605, an Allogeneic BCMA ...

Sep 30, 2020 · CAR T cell total Flux [p/s] Cytokines IL-7 + IL-15 PBS. A. B. Signal 3: Turbodomain (CAR T cell-specific) (A-B) The potential benefit of exogenous cytokine support ...

Cell therapy with human IL-10-producing ILC2s limits ... - Cell ...
Figure 2. Cell therapy with human ILC2 10 suppresses xenogeneic GVHD (A) Overview of the xenogeneic GVHD model to assess whether human ILC2 10 would prophylactically limit ...

Advancing cell-based cancer immunotherapy through stem ...
Advances in cell-based therapy, particularly CAR-T cell therapy, have transformed the treatment of hematological malignancies. Although an important step forward for the eld, autologous ...

Cas-CLOVER is a novel high-fidelity nuclease for safe and
The use of T cells from healthy donors for allogeneic chimeric antigen receptor T (CAR-T) cell cancer therapy is attractive because healthy donor T cells can produce versatile off-the-shelf ...

Autologous Cell Therapy: Key Challenges and Bioprocessing ...
for cell therapy to reach its full potential and successfully address the diverse range of patients who could benefit from the modality. In addition, strong out-of-class competition (e.g., ...

NKG2D and Novel Approaches to Allogeneic CAR T - Celyad
chimeric antigen receptor T cell (CAR T) therapies •Leader in NKG2D receptor CAR T cell therapy landscape •NKG2D receptor CAR T candidates target eight different stress ligands expressed ...

CD19 chimeric antigen receptor-T cells as bridging therapy
B-cell acute lymphoblastic leukemia Allogeneic hematopoietic stem cell transplantation, Chimeric antigen receptor-T Refractory Relapsed ABSTRACT Chimeric antigen receptor (CAR)-T cell ...

Cellular Therapy Products - U.S. Food and Drug Administration
somatic cell therapy is defined as any autologous, allogeneic, or xenogeneic cells that have been propagated, expanded, selected, pharmacologically treated, or ... If the product is a T cell ...

Precision-Engineered Cell Therapy Orca-T Demonstrates ...
Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity Caspian Oliai1, Rasmus T Hoeg2, ...

Allogeneic T Cell Therapy

Allogeneic T Cell Therapy

Related Articles

- alphabet writing fluency wiat 4
- alpha lion dad bod destroyer stack instructions
- ally financial business credit application

Back to Home